Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Pazopanib in renal cell carcinoma Ward JE; Stadler WMClin Cancer Res 2010[Dec]; 16 (24): 5923-7Pazopanib is an oral, multitargeted tyrosine kinase inhibitor that has been approved by the U.S. Food and Drug Administration for treatment of patients with advanced renal cell cancer on the basis of a randomized, double-blind, placebo-controlled, phase III trial, which showed that once a day dosing of 800 mg of pazopanib resulted in progression free survival of 9.2 months versus 4.2 months (P < 0.0001). Pazopanib thus joins sorafenib and sunitinib as one of the clinically available VEGF receptor (VEGFR)-targeted drugs for the treatment of patients with advanced clear cell renal cell cancer. The mechanism of action, preclinical and clinical data, and a comparison with the other drugs in its class are outlined below.|Animals[MESH]|Antineoplastic Agents/therapeutic use[MESH]|Carcinoma, Renal Cell/diagnosis/*drug therapy[MESH]|Clinical Trials as Topic[MESH]|Drug Evaluation, Preclinical[MESH]|Humans[MESH]|Indazoles[MESH]|Kidney Neoplasms/diagnosis/*drug therapy[MESH]|Protein Kinase Inhibitors/therapeutic use[MESH]|Pyrimidines/*therapeutic use[MESH]|Sulfonamides/*therapeutic use[MESH] |
